Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) CEO Sells 53,083 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad Robins sold 53,083 shares of the business’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $15.52, for a total value of $823,848.16. Following the completion of the sale, the chief executive officer owned 1,934,247 shares of the company’s stock, valued at $30,019,513.44. This trade represents a 2.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Adaptive Biotechnologies Trading Down 0.2%

ADPT stock traded down $0.04 during trading hours on Tuesday, hitting $16.08. 1,777,424 shares of the stock were exchanged, compared to its average volume of 1,733,053. The company has a 50-day simple moving average of $16.85 and a two-hundred day simple moving average of $15.79. The firm has a market capitalization of $2.48 billion, a P/E ratio of -40.20 and a beta of 2.19. Adaptive Biotechnologies Corporation has a 12 month low of $6.26 and a 12 month high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. The business had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. Adaptive Biotechnologies’s revenue for the quarter was up 51.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.23) earnings per share. On average, equities research analysts predict that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Institutional Trading of Adaptive Biotechnologies

Several institutional investors have recently modified their holdings of the business. Westfield Capital Management Co. LP bought a new position in Adaptive Biotechnologies during the 4th quarter worth $65,942,000. Price T Rowe Associates Inc. MD raised its position in shares of Adaptive Biotechnologies by 303.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock worth $71,252,000 after acquiring an additional 3,299,635 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in shares of Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after acquiring an additional 2,731,648 shares during the period. Invesco Ltd. boosted its holdings in Adaptive Biotechnologies by 248.8% in the fourth quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock valued at $50,468,000 after acquiring an additional 2,216,595 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its position in Adaptive Biotechnologies by 544.0% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock valued at $36,523,000 after purchasing an additional 2,062,282 shares during the period. Institutional investors own 99.17% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. TD Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. BTIG Research raised their price target on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Wall Street Zen raised shares of Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research note on Sunday, February 8th. Guggenheim upped their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Finally, Morgan Stanley initiated coverage on Adaptive Biotechnologies in a research note on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price target for the company. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Adaptive Biotechnologies currently has an average rating of “Moderate Buy” and a consensus price target of $18.25.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.